Literature DB >> 32884115

Modulation of DNA double-strand break repair as a strategy to improve precise genome editing.

Ujjayinee Ray1, Sathees C Raghavan2.   

Abstract

In the present day, it is possible to incorporate targeted mutations or replace a gene using genome editing techniques such as customisable CRISPR/Cas9 system. Although induction of DNA double-strand breaks (DSBs) by genome editing tools can be repaired by both non-homologous end joining (NHEJ) and homologous recombination (HR), the skewness of the former pathway in human and other mammals normally result in imprecise repair. Scientists working at the crossroads of DNA repair and genome editing have devised new strategies for using a specific pathway to their advantage. Refinement in the efficiency of precise gene editing was witnessed upon downregulation of NHEJ by knockdown or using small molecule inhibitors on one hand, and upregulation of HR proteins and addition of HR stimulators, other hand. The exploitation of cell cycle phase differences together with appropriate donor DNA length/sequence and small molecules has provided further improvement in precise genome editing. The present article reviews the mechanisms of improving the efficiency of precise genome editing in several model organisms and in clinics.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32884115     DOI: 10.1038/s41388-020-01445-2

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  116 in total

Review 1.  The DNA damage response: ten years after.

Authors:  J Wade Harper; Stephen J Elledge
Journal:  Mol Cell       Date:  2007-12-14       Impact factor: 17.970

Review 2.  Snaps and mends: DNA breaks and chromosomal translocations.

Authors:  Saniya M Javadekar; Sathees C Raghavan
Journal:  FEBS J       Date:  2015-05-19       Impact factor: 5.542

Review 3.  Genome-Editing Technologies: Principles and Applications.

Authors:  Thomas Gaj; Shannon J Sirk; Sai-Lan Shui; Jia Liu
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-12-01       Impact factor: 10.005

4.  Comparison of nonhomologous end joining and homologous recombination in human cells.

Authors:  Zhiyong Mao; Michael Bozzella; Andrei Seluanov; Vera Gorbunova
Journal:  DNA Repair (Amst)       Date:  2008-08-20

Review 5.  The democratization of gene editing: Insights from site-specific cleavage and double-strand break repair.

Authors:  Maria Jasin; James E Haber
Journal:  DNA Repair (Amst)       Date:  2016-05-12

6.  One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering.

Authors:  Haoyi Wang; Hui Yang; Chikdu S Shivalila; Meelad M Dawlaty; Albert W Cheng; Feng Zhang; Rudolf Jaenisch
Journal:  Cell       Date:  2013-05-02       Impact factor: 41.582

7.  Highly efficient CRISPR/Cas9-mediated knock-in in zebrafish by homology-independent DNA repair.

Authors:  Thomas O Auer; Karine Duroure; Anne De Cian; Jean-Paul Concordet; Filippo Del Bene
Journal:  Genome Res       Date:  2013-10-31       Impact factor: 9.043

8.  Kinetics and Fidelity of the Repair of Cas9-Induced Double-Strand DNA Breaks.

Authors:  Eva K Brinkman; Tao Chen; Marcel de Haas; Hanna A Holland; Waseem Akhtar; Bas van Steensel
Journal:  Mol Cell       Date:  2018-05-24       Impact factor: 17.970

9.  A generic strategy for CRISPR-Cas9-mediated gene tagging.

Authors:  Daniel H Lackner; Alexia Carré; Paloma M Guzzardo; Carina Banning; Ramu Mangena; Tom Henley; Sarah Oberndorfer; Bianca V Gapp; Sebastian M B Nijman; Thijn R Brummelkamp; Tilmann Bürckstümmer
Journal:  Nat Commun       Date:  2015-12-17       Impact factor: 14.919

Review 10.  Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.

Authors:  Hongyi Li; Yang Yang; Weiqi Hong; Mengyuan Huang; Min Wu; Xia Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-01-03
View more
  8 in total

1.  Network Pharmacology Analysis and Experimental Pharmacology Study Explore the Mechanism of Gambogic Acid against Endometrial Cancer.

Authors:  Zhengxiang Xia; Zhongyan Tang
Journal:  ACS Omega       Date:  2021-04-14

Review 2.  SCR7, a potent cancer therapeutic agent and a biochemical inhibitor of nonhomologous DNA end-joining.

Authors:  Meghana Manjunath; Bibha Choudhary; Sathees C Raghavan
Journal:  Cancer Rep (Hoboken)       Date:  2021-01-26

3.  FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair.

Authors:  Shu-Ping Wang; Shi-Qi Wu; Shi-Hui Huang; Yi-Xuan Tang; Liu-Qiong Meng; Feng Liu; Qi-Hua Zhu; Yun-Gen Xu
Journal:  Cell Death Dis       Date:  2021-12-08       Impact factor: 8.469

4.  Improved loss-of-function CRISPR-Cas9 genome editing in human cells concomitant with inhibition of TGF-β signaling.

Authors:  Tarun Mishra; Vipin Bhardwaj; Neha Ahuja; Pallavi Gadgil; Pavitra Ramdas; Sanjeev Shukla; Ajit Chande
Journal:  Mol Ther Nucleic Acids       Date:  2022-03-08       Impact factor: 8.886

Review 5.  Recent Advances in the Development of Non-PIKKs Targeting Small Molecule Inhibitors of DNA Double-Strand Break Repair.

Authors:  Jeremy M Kelm; Amirreza Samarbakhsh; Athira Pillai; Pamela S VanderVere-Carozza; Hariprasad Aruri; Deepti S Pandey; Katherine S Pawelczak; John J Turchi; Navnath S Gavande
Journal:  Front Oncol       Date:  2022-04-06       Impact factor: 5.738

Review 6.  Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy.

Authors:  Lukman O Afolabi; Mariam O Afolabi; Musbahu M Sani; Wahab O Okunowo; Dehong Yan; Liang Chen; Yaou Zhang; Xiaochun Wan
Journal:  Clin Transl Immunology       Date:  2021-06-22

Review 7.  Current status of the application of gene editing in pigs.

Authors:  Fuminori Tanihara; Maki Hirata; Takeshige Otoi
Journal:  J Reprod Dev       Date:  2021-04-10       Impact factor: 2.214

8.  Screening and validation of genome-edited animals.

Authors:  Rosie K Bunton-Stasyshyn; Gemma F Codner; Lydia Teboul
Journal:  Lab Anim       Date:  2021-07-01       Impact factor: 2.471

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.